8/30/2005

The Maryland biotech said it has acquired worldwide rights from GlaxoSmithKline to develop monoclonal antibodies targeting Staphylococcus bacteria. The drug candidates MedImmune has licensed include BSYX-A110, which is in Phase II trials for preventing bloodstream infections caused by staph in low-birthweight babies.

Related Summaries